Journal of Dermatological Treatment This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

A case of junctional epidermolysis bullosa intermediate with collagen XVII deficiency treated with dupilumab
We describe a case of junctional epidermolysis bullosa that improved with dupilumab.PMID:37968922 | DOI:10.1080/09546634.2023.2253943 (Source: Journal of Dermatological Treatment)
Source: Journal of Dermatological Treatment - November 16, 2023 Category: Dermatology Authors: Li Zhang Shangshang Wang Qinyi Chen Leihong Xiang Source Type: research

Palmoplantar pustulosis with psoriatic arthritis ineffective to interleukin-17 inhibitors: two patients successfully treated with upadacitinib
J Dermatolog Treat. 2023 Dec;34(1):2280508. doi: 10.1080/09546634.2023.2280508. Epub 2023 Nov 15.ABSTRACTPalmoplantar pustulosis (PPP) is a rare chronic pustular disease. Psoriatic arthritis (PsA) is one of the common manifestations of arthritis in PPP associated with a high burden of disease. The treatment of PPP is difficult and still in the exploratory stage. Only a few cases show that PPP complicated with arthritis have been successfully treated with janus kinase inhibition, interleukin (IL)-6 inhibitors, IL-12/23 inhibitors and tumor necrosis factor inhibitors. Here we reported that two patients were diagnosed as PPP ...
Source: Journal of Dermatological Treatment - November 16, 2023 Category: Dermatology Authors: Zeng-Yun-Ou Zhang Wen-Yao Mi Yi-Yi Wang Wei Li Source Type: research

A systematic review investigating at what proportion clinical images are shared in prospective randomized controlled trials involving patients with psoriasis and biological agents
This study aimed to assess the proportion of shared clinical images in psoriasis trials. A systematic review adhering to the PRISMA guidelines was performed. The review was limited to randomized controlled trials, and among these, only investigations involving biological agents for treatment of psoriasis were included. The Embase, MEDLINE and Scopus databases were searched for eligible studies published from inception to October 26, 2021. In total, 152 studies were included. When combining these, 62,871 patients were randomized. Overall, 203 images were shared depicting 60 patients in the manuscripts yielding an overall sh...
Source: Journal of Dermatological Treatment - November 15, 2023 Category: Dermatology Authors: Sam Polesie Farzad Alinaghi Alexander Egeberg Source Type: research

Treatment satisfaction of adult patients with moderate-to-severe atopic dermatitis treated with baricitinib in France, Germany, and the United Kingdom: results from a cross-sectional international patient survey
CONCLUSIONS: Satisfaction with itch control was particularly high, reflected in rates of improvement in itch since starting baricitinib. On the TSQM-9, the convenience score was the highest. Many patients tapered/stopped concomitant topicals, indicating baricitinib's effect in controlling AD symptoms.PMID:37965779 | DOI:10.1080/09546634.2023.2276047 (Source: Journal of Dermatological Treatment)
Source: Journal of Dermatological Treatment - November 15, 2023 Category: Dermatology Authors: Matthias Augustin Audrey Nosbaum Thomas Werfel Susanne Grond Catherine Reed Anastasia Lampropoulou Nicole Tietz Alan D Irvine Elisabeth Riedl Source Type: research

An updated systematic review and meta-analysis of efficacy and safety of Chinese herbal medicine for treating atopic dermatitis
CONCLUSIONS: CHM was effective for treating AD as it could improve the overall recovery rate and decrease the recurrence rate. More studies are required to validate the potential of CHM on disease/symptoms severity and QoL.PMID:37955143 | DOI:10.1080/09546634.2023.2268766 (Source: Journal of Dermatological Treatment)
Source: Journal of Dermatological Treatment - November 13, 2023 Category: Dermatology Authors: Jinjing Jia Sherman X Gu Xiumei Mo Junfeng Liu Dacan Chen Source Type: research

Successful treatment of Langerhans cell histiocytosis in an infant with vemurafenib: a case report and literature review
J Dermatolog Treat. 2023 Dec;34(1):2279901. doi: 10.1080/09546634.2023.2279901. Epub 2023 Nov 9.ABSTRACTLangerhans cell histiocytosis (LCH) is a histiocytic neoplasm characterized by a mass of CD1a + CD207 + histiocytes, exhibiting a diverse range of clinical manifestations from a self-healing rash or single bone destruction to multi-organ disease with potentially fatal consequences. The identification of MAPK signaling pathway activation, particularly BRAFV600E mutations, has propelled targeted therapy into the forefront of therapeutic research for LCH. Several studies have demonstrated that Vemurafenib, a BRAF inhibitor,...
Source: Journal of Dermatological Treatment - November 9, 2023 Category: Dermatology Authors: Qingqing Li Source Type: research